Biomedical subjects
Publications and source records attributed to C Post.
Intrathecal administration of the substance P antagonist Spantide caused marked necrotic changes of the gray matter of the spinal cord extending several segments from the injection site. Intravenous treatment with several doses of thyrotropin releasing hormone before and after Spantide injection completely prevented the necrotic lesion.
The antinociceptive effect elicited by the 5-hydroxytryptamine (5-HT) agonist 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) was reversed or blocked in animals which had previously sustained severe spinal noradrenaline (NA) depletion via either systemic N-2-chlorethyl-N-ethyl-2-bromobenzylamine hydrochloride (DSP 4), neonatal 6-hydroxydopamine (neon. 6-OHDA), or intrathecal 6-OHDA treatment. Biochemical analysis of the lumbar spinal cord samples confirmed severe central NA depletions. Animals were tested with nondamaging heat pain (tail-flick test, hot-plate test) and electric footshock titration to determine the amount of antinociception or nociception. Peripheral NA depletion following intravenous (i.v.) 6-OHDA injection to adult rats had no effect on the antinociception induced by 5-MeODMT, but did cause severe NA depletions in the left heart atrium. These results suggest a modulatory effect of central and not peripheral noradrenergic system upon 5-HT agonist induced analgesia, and also give evidence that this effect is spinally mediated.
Intrathecal injections in mice of substance P (SP), capsaicin and kainic acid elicited a behavioural response similar to that caused by noxious stimulation. Although the agents have different mechanisms of action, they showed a similar response, consisting of biting, scratching and licking the caudal parts of the body. Activation of adenosine receptors in the spinal cord with 5-N-ethylcarboxamide adenosine (NECA) had no effect on the response to substance P or to kainic acid, but reduced the response to capsaicin. It is concluded that different substances, injected intrathecally, can be used to differentiate between pre- and postsynaptic induced nociceptive behaviour, and that this assay may be valuable in assessing central antinociceptive effects of various drugs, especially those affecting systems modulated by substance P.
The ability of 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT) to alter nociceptive sensitivity in mice was studied using the tail-flick, hot-plate and formalin tests. Subcutaneous (SC) administration of 8-OH-DPAT (0.63-1.0 mg/kg) dose-dependently increased the temperature at which hindpaw lick occurred in a hot-plate test using slowly rising temperature and increased the latencies to hindpaw lick, but reduced the latencies to jump in a conventional hot-plate test. Intracerebroventricular (ICV) injections (0.25-1.0 microgram) produced similar results in the conventional hot plate test. Following intrathecal (ITH) injections (0.25-1.0 microgram), however, the latencies to hindpaw lick were elevated without any change in jump latencies. In the formalin test a low systemic dose of 8-OH-DPAT (0.063 mg/kg) elicited hyperalgesia, while hypoalgesia was found after a high dose (1.0 mg/kg). ICV injection of 1.0 microgram produced hypoalgesia in the formalin test while the same dose injected ITH was without effect. 8-OH-DPAT did not alter tail-flick latencies, either by SC, ICV or ITH administration. Previous studies have shown that 8-OH-DPAT stimulates central serotonergic receptors, and shows selectivity for the 5-HT1A recognition site. The present findings indicate an involvement of 5-HT1A receptors in the processing of nociceptive information both at spinal and supraspinal sites. However, stimulation of 5-HT1A receptors does not seem to affect spinal, nociceptive reflexes.
Two experiments were performed on Sprague-Dawley rats to study the effects of noradrenaline and 5-hydroxytryptamine depletion upon the antinociceptive effects of acute 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) administration. 6-Hydroxydopamine-induced lesions following microinjections to either the locus coeruleus or the spinal cord (lumbar) abolished completely 5-MeODMT-induced analgesia in the tail-flick, hot-plate, and shock titration tests whereas 5,7-dihydroxytryptamine-induced lesions of the nucleus raphe magnus and the lumbar spinal cord attenuated 5-MeODMT analgesia in the tail-flick and shock titration tests. Thus, the experiments serve to demonstrate an important interaction between descending noradrenergic and serotonergic pathways, possibly at a spinal locus.
The effects of the alpha-adrenoceptor antagonists prazosin, phentolamine and yohimbine upon 5-methoxy-N,N-dimethyltryptamine (5-MeODMT)-induced analgesia were tested in the hot-plate, tail-flick and shock-titration tests of nociception with rats. Intrathecally injected yohimbine and phentolamine blocked or attenuated the analgesia produced by systemic administration of 5-MeODMT in all three nociceptive tests. Intrathecally administered prazosin attenuated the analgesic effects of 5-MeODMT in the hot-plate and tail-flick tests, but not in the shock titration test. Intrathecal yohimbine showed a dose-related lowering of pain thresholds in saline and 5-MeODMT-treated animals. Phentolamine and prazosin produced normal dose-related curves in the hot-plate test and biphasic effects in the shock titration and tail-flick tests. These results demonstrate a functional interaction between alpha 2-adrenoceptors and 5-HT agonist-induced analgesia at a spinal level in rats.
Antinociceptive effects of intrathecal injections of morphine and pethidine were evaluated in rats using the hot-plate and tail-flick tests. Both drugs elicited antinociceptive effects either it was evaluated with maximal response latency (sec.) or with area under the curve (AUC) (sec. X min.). The effects of pethidine were shortlived. The concentration of morphine in the spinal cord correlated to its antinociceptive effects when tested on hot plate. A minimal morphine concentration of 3 pmol/mg in the spinal cord was required to induce experimental analgesia in the rat.
The effect of chronic and acute oral or intraperitoneal treatment with the antidepressant drugs, desipramine, amitriptyline, alaproclate and iprindole, upon pain thresholds in the tail flick, hot plate and shock titration tests of nociception in saline- and 5-MeODMT-treated rats was studied. Chronic desipramine treatment increased the pre-test tail flick latencies. In the saline-treated rats, chronic oral desipramine treatment increased tail flick latencies, whereas chronic oral amitriptyline treatment decreased tail flick latencies. In 5-MeODMT-treated rats, chronic oral desipramine treatment attenuated the effects of 5-MeODMT (1 mg/kg) in all three tests of nociception, whereas chronic amitriptyline caused a potentiation in the tail flick and hot plate tests. Chronic oral iprindole treatment attenuated 5-MeODMT-induced analgesia in the hot plate test. Chronic intraperitoneal desipramine treatment attenuated 5-MeODMT analgesia in the tail flick and shock titration tests. In a different chronic treatment experiment, oral desipramine treatment attenuated 5-MeODMT analgesia in the tail flick test and zimeldine did for both the tail flick and hot plate tests, whereas mianserin potentiated 5-MeODMT-induced analgesia in both the tail flick and hot plate tests. In the saline-treated rats, acute treatment with all four drugs, desipramine, amitriptyline, iprindole and alaproclate, elevated the shock thresholds, whereas in 5-MeODMT-treated rats, desipramine and amitriptyline elevated shock thresholds. Two main conclusions can be drawn: chronic desipramine caused a quite consistent attenuation of 5-MeODMT-induced analgesia and the effects of acute treatment differed strongly from that of the chronic treatment. The effects of chronic administration with these antidepressants were compared with other findings using different measures of behavioural and receptor function.
Explore the source record for details and available documents.
Experiments were done to assess the relationship of the chemical properties of local anesthetics to their ability to block neuronal impulse conduction, using a series of hitherto unavailable homologs of lidocaine. These molecules varied in the number and arrangement of alkyl groups attached to the tertiary amine nitrogen. Each compound was applied to desheathed sciatic nerves of frogs (Rana pipiens) mounted in a sucrose gap recording chamber. Compound action potentials (AP) were recorded at room temperature (20-23 degrees C) and the potency of each anesthetic determined from the concentration required to produce a 40% reduction in the amplitude of the AP at low-frequency stimulation: 1 min-1. This reduction was called Bt. An additional Bt was measured from the further decrease in amplitude of the AP during high-frequency stimulation (10 and 40 Hz). Tonic and phasic blocking potencies were analyzed as functions of the calculated drug partition coefficients, and the known molecular weights, molecular configurations and pKa values. Potency for Bt increased with increasing length of n-alkyl groups attached to the terminal amine, whereas it decreased as the length of the alkyl group connecting the amide bond to the terminal amine was increased. However, when considered in terms of their physicochemical properties, the homologs showed a potency for Bt that increased uniformly with increasing partition coefficient. This analysis revealed a strong positive correlation between tonic potency and partitioning into octanol for both neutral and protonated anesthetic species but little correlation with molecular weight or pKa. However, Bt did not depend uniquely on hydrophobicity, as predicted if lipophilic partitioning alone determined potency.(ABSTRACT TRUNCATED AT 250 WORDS)
Clonidine has been reported to produce analgesia in man after epidural and intrathecal administration. In the present investigation the alpha 2-adrenoceptor agonists clonidine and guanfacine were tested to evaluate their potential spinal neurotoxic effects. Rats were injected daily for 14 consecutive days via catheters implanted in the intrathecal space. Clonidine was administered at a dose of 1.63 micrograms or 16.3 micrograms, and guanfacine at 16.3 or 75 micrograms. After perfusion with a buffered 3% glutaraldehyde solution, the spinal cords and nerve roots were taken for neuropathological analysis using light and electron microscopy. Compared to animals injected with 0.9% saline, clonidine and guanfacine gave rise to no detectable neurotoxic changes in the doses employed. An additional group of rats had intrathecal injections of a substance P-antagonist (D-Arg1, D-Trp7,9, Leu11)-substance P (spantide) with known neurotoxic effect as a test of the histotechnical methods used. Degenerative lesions, with a preference for the ventral horns, were consistently present in the grey matter of the cord in these animals. We conclude that the absence of detectable changes in rats given clonidine and guanfacine is probably a real expression of the low degree of toxicity for these compounds on rat spinal cord and nerve roots and not an artifact of the sensitivity of the histotechniques applied. The doses of clonidine administered were considerably greater than those reported to produce clinical greater than those reported to produce clinical analgesia.
Contrary to what would have been expected, an antagonist of substance P (SP) [Arg5,D-Trp7,9]SP-(5-11) inhibited the neurogenic contraction of isolated guinea-pig hilus bronchi more readily than a contraction produced by exogenous SP. Furthermore, it has previously been shown that a tachykinin antagonist given intrathecally produced motor blockade as do local anaesthetic drugs. We therefore examined whether tachykinin antagonists had a depressant action on axonal neurotransmission. The compound action potential (APc) of the frog isolated sciatic nerve was suppressed in a concentration-dependent manner by the tachykinin antagonists [D-Pro2,D-Trp7,9]SP and [Arg5,D-Trp7,9]Sp-(5-11), both being about 4 times more potent than lidocaine. SP itself was without effect. Similarly in the rat isolated sciatic nerve [D-Pro2,D-Trp7,9]SP suppressed the APc. It was more potent in the A alpha- than in the C-fibres. SP did not affect conduction in either fibre type. In conscious guinea-pigs [D-Pro2,D-Trp7,9]SP injected adjacent to the sciatic nerve was found to block motor but not sensory functions of the limb. Thus, commonly used tachykinin antagonists, but not SP itself, have potent local anaesthetic properties. This should be considered when these agents are employed as pharmacological tools.
Mice were treated with N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride (DSP4), which causes severe noradrenaline (NA) depletions in brain regions and the spinal cord, or vehicle i.p. They were tested 14 days later for antinociception induced by intrathecal injections of different doses of NA. A potentiation of the NA effect upon pain sensitivity was observed, with both an increase in the magnitude and duration of the antinociceptive responses. Upon biochemical analysis of spinal cords, it was found that DSP4-treated mice had a 80% depletion of NA, whereas dopamine and 5-hydroxytryptamine were unaffected. Radioligand binding of [3H]clonidine in membranes prepared from spinal cord, showed no differences in density of alpha 2-adrenoceptors, but the affinity had been increased, probably explaining the supersensitivity.
The antinociceptive effects and antagonism of substance P (SP)-induced behaviour were examined after intrathecal injections in mice. When coadministered with SP, the SP analogues attenuated the SP-induced behaviour to various extents with [D-Arg1,D-Pro2,4,D-PHe7,D-His9]SP as the most potent antagonist. Physalaemin and eledoisin brought about a SP-like behavioural response. [D-Arg1,D-Trp7,9,Leu11]SP inhibited the response to eledoisin but not that to physalaemin. The SP analogues substituted with D-Trp7,9 and with Leu or Val in position 11 produced the strongest antinociceptive effects. Pretreatment with naloxone (5 mg/kg, i.p.) abolished the antinociceptive effects of [D-Trp7,9,Leu11]SP, implying that opiate receptors in the spinal cord mediate at least in part the antinociceptive effects. Animals under pentobarbital anesthesia showed a potentiated antinociceptive effect in the tail-flick test. In conclusion, we found that the SP analogues tested exerted varying degrees of antinociception, and that this was probably at least in part mediated by activation of spinal opiate receptors, whereas the behavioural antagonism was probably due to the blockade of spinal SP receptors.
Intrathecal administration of both (D-Pro2,D-Trp7,9)-substance P (DPDT) and (D-Arg1,D-Trp7,9,Leu11)-substance P (DADTL) elicited antinociception in hot-plate and tail-flick test, with DADTL as the most potent. The animals injected with 2.0 micrograms DADTL, and several animals administered with DPDT at the same dose, developed bilateral motor blockade of the hind-legs, persisting for up to 3 days after DADTL. The effect of DPDT appeared to be reversible at this dose. On histopathological examination it was found that these animals with persistent paralysis had widespread neuronal necrosis in the lumbar region of the spinal cord. It is concluded that the peptides have antinociceptive effects after the intrathecal administration in rats, but that there is a small margin between the dose producing this effect and that causing irreversible toxic reactions in the spinal cord.
The acute effects of the 5-hydroxytryptamine agonist, 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), upon pain sensitivity, using shock titration, tail-flick and hot-plate methods, in noradrenaline- and 5-hydroxytryptamine-depleted rats were examined. Noradrenaline depletion, following the systemic administration of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride (DSP4, 2 X 50 mg/kg, i.p.), caused a reversal of the analgesic effect of 5-MeO-DMT on shock-titration from hypo- to hypersensitivity, and a total blockade of the antinociceptive effect of 5-MeO-DMT upon pain responses in the hot-plate and tail-flick tests. Pretreatment with either p-chloroamphetamine (2 X 10 mg/kg) or p-chlorophenylalanine (200, 100, 100 mg/kg), that depletes central 5-hydroxytryptamine stores, failed to alter the analgesia caused by acute 5-MeO-DMT. Strong evidence is provided for the effect of central noradrenaline depletion upon the analgesic effect of the 5-HT agonist. These findings suggest an important tonic influence of the noradrenaline system upon the descending spinal 5-HT pathway in rats.
The analgesic effect of 5-hydroxytryptamine (5-HT, 200 and 250 micrograms/kg) administered into the lumbar intrathecal space of rats was blocked in the tail-flick, hot-plate and shock titration tests of nociception when the animals had previously been treated with N-2-chloroethyl-N-ethyl-2-bromobenzylamine (DSP4), which depletes noradrenaline in the spinal cord. These results suggest an important modulatory role of noradrenaline upon spinal 5-HT mechanisms.
Redistribution of lidocaine and bupivacaine was studied after intrathecal injection in mice qualitatively by whole-body autoradiography or quantitatively by determining spinal cord concentration of the drugs. The composition of the drug solutions then were changed to see if drug distribution could be altered. Changing the pH of the lidocaine solution from 7.5 to 5.0 by adding hydrochloric acid had no effect on spinal cord distribution. Simultaneous injection of bupivacaine and epinephrine increased the bupivacaine concentration in the spinal cord. By adding sucrose to a lidocaine solution, rostral spread of lidocaine was considerably less when the animals were restrained in a vertical position as compared with those injected with a plain solution. When lidocaine and bupivacaine were injected simultaneously, the spinal cord concentration was only changed to a small extent as compared with when the drugs were given separately. Whole body autoradiography revealed that both lidocaine and bupivacaine were rapidly redistributed rostrally from the lumbar area, but quantitatively the rostral redistribution is small. Whole body autoradiography also illustrated the elimination pathways from the spinal subarachnoid space. The authors conclude that alterations in the composition of the injected drug solution can affect rostral redistribution in the spinal cord tissue.